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Podoplanin is a transmembrane O-glycoprotein that
binds to C-type lectin-like receptor 2 (CLEC-2).
The O-glycan-dependent interaction seems to play
crucial roles in various biological processes, such
as platelet aggregation. Rhodocytin, a snake venom,
also binds to CLEC-2 and aggregates platelets in a
glycan-independent manner. To elucidate the struc-
tural basis of the glycan-dependent and independent
interactions, we performed comparative crystallo-
graphic studies of podoplanin and rhodocytin in
complex with CLEC-2. Both podoplanin and rhodo-
cytin bind to the noncanonical ‘‘side’’ face of CLEC-
2. There is a common interaction mode between
consecutive acidic residues on the ligands and the
same arginine residues on CLEC-2. Other inter-
actions are ligand-specific. Carboxyl groups from
the sialic acid residue on podoplanin and from the
C terminus of the rhodocytin a subunit interact
differently at this ‘‘second’’ binding site on CLEC-2.
The unique and versatile binding modes open a
way to understand the functional consequences of
CLEC-2-ligand interactions.
INTRODUCTION
In vertebrates, the growth of blood vessels (angiogenesis) and
lymphatic vessels (lymphangiogenesis) involves the coordi-
nation of many biological processes such as cell proliferation,
migration, and cell-cell communication (Adams and Alitalo,
2007). The mechanism of angiogenesis has received consider-
able attention over the past few decades. However, the pro-
cesses regulating lymphangiogenesis have only been explored
very recently (Tammela and Alitalo, 2010). CLEC-2 (CLEC1B) is
a type II transmembrane, C-type lectin-like receptor (Figure 1),
and its activation in platelets blocks lymphaticovenous connec-
tions, thereby helping to separate blood and lymphatic vascular
systems. CLEC-2 was first identified as a cell surface protein
expressed in the liver and blood cells, mostly of myeloid originStructure 22, 1711–17(Colonna et al., 2000), and then recognized as the receptor for
rhodocytin, the snake venom toxin. Rhodocytin, produced by
the Malayan pit viper (Calloselasma rhodostoma) is a nongly-
cosylated heterodimeric protein composed of one a and one b
subunit (Shin and Morita, 1998) (Figure 1) and induces platelet
aggregation (Suzuki-Inoue et al., 2006). Subsequently, CLEC-2
was found to be the physiological receptor for the O-glyco-
sylated protein podoplanin (also known as aggrus, OTS8, T1a,
E11 antigen, gp38, and PA2.26) (Suzuki-Inoue et al., 2007).
Podoplanin is a type I sialomucin-like glycoprotein expressed
in the cardinal vein and lymphatic endothelial cells (Figure 1).
Podoplanin-deficient mice have abnormal lymphatic vessels
because of blood-lymphatic misconnections (Schacht et al.,
2003). Importantly, the same abnormality occurs in mice lacking
glycosyltransferase T-synthase (C1galt1), an enzyme critical for
the expression of podoplanin, suggesting that O-glycosylation
is required for podoplanin function (Fu et al., 2008). Furthermore,
conditional knockout of CLEC-2 in platelets impairs blood/
lymphatic vessel separation (Osada et al., 2012). Activation of
CLEC-2 by binding O-glycosylated podoplanin is, therefore,
essential for blood/lymphatic separation.
Accumulating evidence suggests that many other important
biological pathways depend on the CLEC-2-podoplanin inter-
action. CLEC-2 deficiency in dendritic cells impairs their entry
into the lymphatics and their migration to lymph nodes (Acton
et al., 2012). Podoplanin expressed on fibroblastic reticular
cells activates CLEC-2 on extravasated platelets in the perive-
nular space of high endothelial venules (HEVs), thus maintain-
ing HEV integrity during immune responses (Herzog et al.,
2013). The importance of podoplanin has been highlighted by
its frequent upregulation in tumors. Podoplanin is overex-
pressed in human and murine tumors in various tissues (Kato
et al., 2003, 2005; Kato and Kaneko, 2014) and enhances
hematogenous metastasis by inducing platelet aggregation
through activation of CLEC-2 (Kato et al., 2008). In this context,
an anti-human podoplanin antibody, NZ-1 (Kaneko et al., 2012;
Kato et al., 2006, 2010), which inhibits podoplanin-induced
platelet activation, abrogates tumor metastasis by inhibiting
the interaction of podoplanin and CLEC-2 (Figure 1A). CLEC-
2 features in viral infections. CLEC-2 on platelets is an attach-
ment factor for HIV type 1 (HIV-1) and mediates HIV-1 capture
through the C-type lectin receptor DC-SIGN (Chaipan et al.,
2006, 2010).21, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1711
Figure 1. Molecular Interactions of CLEC-2 and Podoplanin
(A) Interaction of CLEC-2 and O-glycosylated podoplanin (physiologically a trans cell-cell interaction). Snake toxin rhodocytin and the anti-podoplanin antibody
NZ-1 block the interaction. hemITAM, hemi-immunoreceptor tyrosine-based activation motif.
(B) Domain architecture of human podoplanin, CLEC-2, and rhodocytin. The amino acid sequence of three consecutive PLAG domains (PLAG1–PLAG3) is
shown, andO-glycosylated Thr52 is indicatedwith asterisk. The N- andC-terminal sequences of the rhodocytin a subunit, which is crucial for CLEC-2 binding, are
indicated. SP, signal peptide; TM, transmembrane domain; CT, cytoplasmic tail.
Structure
Versatile Ligand Recognition Mechanism of CLEC-2Podoplanin contains the well conserved three tandem repeats
of the platelet aggregation-stimulating (PLAG) domain in the
extracellular region (Figure 1B) (Kaneko et al., 2006). In humans,
only the third PLAG domain, PLAG3, has an attached O-glycan,
at Thr52 (Kaneko et al., 2007). Its structure is primarily a disialyl
core 1 (NeuAca2-3Galb1-3(NeuAca2-6)GalNAca1-O-Thr) (Fig-
ure 2A) (Kaneko et al., 2007). Because sialylation is essential
for podoplanin-induced platelet aggregation, CLEC-2 must
specifically recognize the sialylated PLAG3 domain. This seems
at odds with the fact that rhodocytin interacts with CLEC-2 in the
absence of carbohydrate. The structural basis for these specific
interactions is still unknown.
Here we report the crystal structures of the CLEC-2 lectin
domain in complex with podoplanin O-glycosylated peptide
or nonglycosylated rhodocytin. The ligands bind at a locus
distinct from the canonical binding site, and both use a two-
site interaction mode. The C-type lectin fold displays an unex-
pected binding versatility, and the details of this binding mode,
described here, may help in the rational design of anti-platelet
aggregation lead compounds.
RESULTS
The Structure of CLEC-2 Complexed with the
O-Glycosylated Podoplanin PLAG Domain
We determined the crystal structure, at 1.9 A˚ resolution, of
a complex of the CLEC-2 extracellular lectin domain and a
podoplanin glycopeptide encompassing the PLAG2 and PLAG3
domains (Glu38–Gly54) with a disialyl core 1O-glycan (NeuAca2-
3Galb1-3[NeuAca2-6]GalNAca1-O-Thr) at Thr52 (Figure 2A,
Table 1). The asymmetric unit contains two copies of the1712 Structure 22, 1711–1721, December 2, 2014 ª2014 Elsevier LtdCLEC-2-podoplanin complex (Figure 2B). The two complexes,
referred to as complex A and complex B, include Pro101–
Ala220 of CLEC-2 and Ala46–Gly54 and Gly45–Gly54 of the po-
doplanin peptide, respectively. Structural superposition of the
two complexes in the asymmetric unit revealed that the root-
mean-square deviation (rmsd) of 120 corresponding Ca atoms
of CLEC-2 is only 0.4 A˚ (Figure S1A available online). In both com-
plexes, the PLAG2 (Glu38–Gly45) domain and a2-3 linked sialic
acid are exposed to solvent, and the corresponding electron den-
sities are missing (Figure 2C). Two podoplanin peptides in the
asymmetric unit were disulfide-linked with C terminus cysteine
residues (Figure 2B). Structural superposition of ligand-bound
CLEC-2 with a ligand-free form (Watson et al., 2007) showed
only 0.7 A˚ rmsd for 120 corresponding Ca atoms (Figure S1B),
indicating no apparent structural change on binding.
CLEC-2 Utilizes Its Noncanonical Side Face for Binding
to Sialylated O-Glycan and the Adjoining Polypeptide
of Podoplanin
In complexes A and B, the podoplanin-CLEC-2 interaction
modes are almost identical (Table S1), and only that of complex
A is described hereafter. The C terminus of the PLAG3 domain
points in a different direction than the N terminus of CLEC-2 (Fig-
ure 2D), an orientation befitting trans cell-cell interaction via the
two proteins (Figure 1A). The PLAG3 domain and attached
O-glycan fit into a noncanonical pocket formed by a1 and a2
helices and b1 and b10 strands of the CLEC-2 lectin domain, a
position completely separate from the usual sugar-binding site
(b3 and b4 strands) of typical C-type lectins (Figure 2D). Bound
PLAG3 peptide has no particular secondary structure. Interac-
tion with CLEC-2 is mainly observed at Glu47 and Asp48 in theAll rights reserved
Figure 2. Crystal Structure of CLEC-2 Complexed with the O-Glycosylated Podoplanin PLAG Domain
(A) The O-glycosylated podoplanin peptide (Glu38–Gly54) used in this study (top panel). An artificial cysteine residue is introduced at the C terminus. The gray
parts are the amino acid and carbohydrate residues with missing electron density in the crystal structure. The chemical structure of O-glycan (disialyl core 1)
attached on Thr52 is shown in the bottom panel. The a2-6-linked sialic acid residue, which extensively interacts with CLEC-2, is highlighted in yellow.
(B) Two CLEC-2-podoplanin complexes (A and B) in the asymmetric unit. Two CLEC-2 lectin domains bind to disulfide-linked podoplanin peptides. CLEC-2 and
the podoplanin peptide are shown as ribbon and wire models, and O-glycan attached at Thr52 is shown as a rod model.
(C) The observed electron density of podoplanin. The omit map of the ligand contoured at the 2.5 s level is shown as cyan mesh. The ligand is shown as a rod
model. The peptide and carbohydrate moieties of podoplanin are shown in yellow and white, respectively.
(D) The overall structure of the CLEC-2-podoplanin complex. The secondary structure element numbering of the CLEC-2 lectin domain is based on a previous
report (Zelensky and Gready, 2005). The directions toward membranes are indicated with black arrows.
Structure
Versatile Ligand Recognition Mechanism of CLEC-2PLAG3 domain and the a2-6 linked sialic acid residue (Figure 3A;
Table S1). The side chains of the two acidic residues make elec-
trostatic contact with three arginine residues (Arg107, Arg152,
and Arg157) of CLEC-2 (Figure 3B). The Asp48 side chain is
further connected by hydrogen bonds with the Thr153 side chain
and the backbone of His154 of CLEC-2. The a2–6-linked sialic
acid residue interacts extensively with CLEC-2 (Figure 3C). The
carboxyl group of the sialic acid bonds with the side chain
and backbone atoms of Arg118. The hydroxyl groups OH8 and
OH9 make hydrogen bonds with the side chains of His119 and
Tyr129, respectively, and the N-acetyl oxygen atom interacts
with the side chain of Asn105. Furthermore, the hydrophobic
face of the sialic acid is surrounded by the aromatic rings of
Trp106 and Phe117. The main chain atoms of Asp49-Val50-
Val51, but not the side chain atoms, hydrogen bond with the
side chain of Arg118 of CLEC-2 (Figure 3B). The mode of inter-
action suggests that CLEC-2 has a recognition motif in the
form ‘‘EDXXXT/S,’’ where X is any amino acid and T (or S) con-Structure 22, 1711–17tains core 1 O-glycan with a2–6 linked sialic acid linked through
an N-acetyl-D-galactosamine (GalNAc) residue. The sequence
motif is conserved among podoplanins of various species
(Figure 4A) (Kaneko et al., 2006).
The a2-6-Linked Sialic Acid Residue Is Essential
for CLEC-2 Binding
The contact surface area of the a2-6-linked sialic acid residue
(247 A˚2) is almost equal to those of the two consecutive acidic
residues (Glu47 and Asp48, 247 A˚2), suggesting that these
two regions contribute significantly to complex formation. To
examine the contribution of the O-glycan part for binding
CLEC-2, we performed a solution nuclear magnetic resonance
(NMR) analysis using glycosylated and nonglycosylated podo-
planin peptides (Figure 3D). The addition of nonglycosylated
PLAG3 peptide to CLEC-2 solution did not significantly change
the 1H-NMR spectrum of CLEC-2. In contrast, the addition of the
podoplanin peptide with a disialyl core 1 O-glycan significantly21, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1713
Table 1. Data Collection and Refinement Statistics
Crystal
CLEC-2-Podoplanin
Complex
CLEC-2-Rhodocytin
Complex
Data Collection Statistics
Space group P21 C2
Cell constant a = 54.4, b = 51.2,
c = 54.1 A˚, b = 112.8
a = 130.9, b = 117.1,
c = 152.2 A˚, b = 115.8
Beamline AR-NW12A BL-5A
Wavelength (A˚) 1.0000 1.0000
Resolution (A˚)a 100–1.90 (1.93–1.90) 100–3.00 (3.05–3.00)
Completeness (%)a 100 (100) 99.7 (99.9)
Rsym (%)
a 7.2 (49.5) 9.9 (45.8)
Redundancy a 4.1 (4.1) 3.6 (3.6)
<I/sI>a 24.3 (3.3) 16.9 (2.9)
Refinement Statistics
Resolution (A˚) 50.13–1.91 37.56–2.98
R (%) 21.9 28.4
Rfree (%) 25.9 32.5
Rmsd from Ideal Values
Bond length (A˚) 0.009 0.009
Bond angle () 1.386 1.619
Average B factor (A˚2) 28.0 60.9
Ramachandran Plot
Favored (%) 97.6 92.7
Allowed (%) 2.4 7.1
Outlier (%) 0.0 0.2
aValues in parentheses are the highest-resolution shells.
Structure
Versatile Ligand Recognition Mechanism of CLEC-2broadened the signals originating fromCLEC-2, clearly indicating
a glycosylation-dependent CLEC-2 interaction. The broadening
of the CLEC-2 signals can be interpreted as formation of the
2+2 dimer observed in the crystal. The solution NMR analysis
supports the conclusion that the a2-6 sialic acid residue is
essential for the interaction.
Arginine Residues on CLEC-2 Are Essential
for Podoplanin Binding
To evaluate the contribution of each arginine residue of CLEC-2
to podoplanin binding, we constructed four CLEC-2 lectin
domain mutants (R107A, R118A, R152A, and R157A) fused to
Fc proteins (Figure S8) and performed a flow cytometric assay
using podoplanin-expressing Chinese hamster ovary (CHO) cells
(Figure 3E). All four alanine mutants failed to bind podoplanin-
expressing cells, indicating that the arginine residues are critical.
CLEC-2 Utilizes the Same Side Face for Binding
to Rhodocytin
To compare the interaction mode of podoplanin with that of the
nonglycosylated ligand rhodocytin, we further solved the crystal
structure of the CLEC-2 lectin domain in complex with rhodo-
cytin at a 3.0 A˚ resolution. The asymmetric unit of the crystal
contains four CLEC-2-rhodocytin complexes. In each complex,
one CLEC-2 lectin domain interacts with one rhodocytin
molecule via the a´ subunit (Figure 5A). The a and b subunits of1714 Structure 22, 1711–1721, December 2, 2014 ª2014 Elsevier Ltdrhodocytin possess C-type lectin folds and form a domain-
swapped dimer, as observed in typical snake venom C-type
lectin domains (Zelensky and Gready, 2005). In the crystal, the
rhodocytin a subunit, b subunit, and CLEC-2 lie along a straight
line. Structural superposition of the four complexes reveals that
the rhodocytin molecules bend slightly at the hinge region of the
domain-swapped dimer (Figure S2). Rhodocytin binds to the
same face of CLEC-2 as podoplanin, except that rhodocytin
only interacts through the N- and C-terminal regions of its a sub-
unit (Figure 5B; Table S2). The contact surface of rhodocytin is
337–446 A˚2 (Table S2). Therefore, it is almost comparable with
that of podoplanin. The N-terminal loop region of the rhodocytin
a subunit contains three acidic residues, Glu3, Asp4, and Asp6,
and these three residues are located close to four basic residues
of CLEC-2, Arg107, Arg118, Arg152, and Arg157. Intriguingly,
the carboxyl group of C-terminal Tyr136 in the rhodocytin a
subunit also resides close to Arg118 of CLEC-2. The additional
backbone interactions seem to stabilize complex formation (Fig-
ure 5C; Table S2). The electrostatic interaction may be important
for complex formation between the negatively charged rhodocy-
tin and the positively charged CLEC-2.
Podoplanin and Rhodocytin Interact with Common
Arginine Residues on CLEC-2
To confirm the contributions of the four arginine residues to rho-
docytin binding, we performed surface plasmon resonance
assays using rhodocytin and a set of CLEC-2 lectin domain mu-
tants. Rhodocytin was immobilized on a sensor chip, and control
CLEC-2 or its mutants were injected as analytes. The maximum
resonance units (RUmax) were plotted against a series of concen-
trations of analytes (Figure 5D). From a steady-state analysis, the
KD of control CLEC-2 was estimated to be 3 mM, which is com-
parable with that of a previous report (1 mM;Watson et al., 2007).
All arginine mutations in CLEC-2 greatly reduce the affinity for
rhodocytin. Evidently, these four arginine residues are essential
for binding rhodocytin and podoplanin.
DISCUSSION
Generally, C-type lectins bind to both carbohydrate and protein
ligands through the ‘‘top’’ face (b3 and b4 strands) of the lectin
(Drickamer, 1999; Zelensky and Gready, 2005). The carbohy-
drate moiety binds via a calcium ion coordinated at this site.
A typical example is the complex between P-selectin and sialyl
LewisX-containing PSGL-1 (Figure 6B; Somers et al., 2000).
The interaction mode of CLEC-2 as elucidated in our study is
quite different (Figure 6A). CLEC-2 lacks the critical calcium-
binding site for carbohydrate recognition (Figure 4C) and binds
the O-glycosylated peptide ligand on the side face (a1, a2, b1,
and b10) with no calcium assistance (Figure 3C) aswell as nongly-
cosylated rhodocytin (Figure 5B). The ligand-binding site on
CLEC-2 is characterized by a clustering of arginine residues.
An electron surface potential map shows a large positive patch
around the ligand binding site (Figure S3).
Structural comparison of CLEC-2-podoplanin and CLEC-2-
rhodocytin complexes reveals no apparent difference in CLEC-
2 structures (Figure 7A). Intriguingly, the N-terminal region of
the rhodocytin a subunit contains a ‘‘Glu-Asp’’ sequence, and
the spatial position of this region relative to CLEC-2 coincidesAll rights reserved
Figure 3. Dual Recognition of CLEC-2 for Podoplanin
(A) The binding interface of the podoplanin peptide (wire model) and the CLEC-2 lectin domain (surface model). Two acidic residues (Glu47 and Asp48) and
carbohydrate moieties are shown as rod models and in yellow. The critical amino acid residues of CLEC-2 are mapped and labeled.
(B) The interaction between CLEC-2 and the podoplanin peptide. Amino acid residues involved in the interactions are shown as rod models. Electrostatic
interactions and hydrogen bonds are represented as red dashed lines.
(C) Recognition of the a2-6-linked sialic acid residue-intermolecular hydrogen bonds and hydrophobic contacts.
(D) CLEC-2 binds O-glycosylated podoplanin peptides, but not unglycosylated peptides, in solution. Shown are the 1H-NMR spectra (methyl region) of 100 mM
CLEC-2 lectin domain in the absence of ligand (top panel), in the presence of 200 mM nonglycosylated PLAG3 domain (center panel), and 200 mM glycosylated
PLAG2-3 domain (bottom panel).
(E) Flow cytometry analysis using Fc-fused CLEC-2 lectin domains and podoplanin-expressing CHO cells.
Structure
Versatile Ligand Recognition Mechanism of CLEC-2well with that of the podoplanin PLAG3 domain (left panel in Fig-
ure 7B). Both complexes exhibit a two-locus interaction, and
both use the Glu-Asp signature (Figure 7C). The negatively
charged patch of the Glu-Asp doublet accepts the positively
charged patch formed by Arg107, Arg152, and Arg157. The
second binding sites are slightly apart, although the carboxyl
groups of both the sialic acid on podoplanin and of the
C terminus of rhodocytin interact with Arg118 on CLEC-2. In
comparison with the rhodocytin complex, the sialic acid in
the podoplanin complex is positioned on the opposite side of
the side chain of Arg118 in CLEC-2 (right panel in Figure 7B).
Therefore, CLEC-2 possesses three ligand binding sites. One
is common to both podoplanin and rhodocytin (site 1), but the
other sites (sites 2 and 3) are ligand-specific. Each ligand uses
its own second binding site (site 3 for podoplanin and site 2 for
rhodocytin) (Figure 7C).Structure 22, 1711–17The human PLAG2 domain lacks the Glu-Asp doublet (corre-
sponding to Glu47–Asp48 in the PLAG3 domain) and the
O-glycosylation site, and the domain does not contribute to
CLEC-2 binding. The PLAG1 domain does have the doublet.
However, there is no attached O-glycan (Kaneko et al., 2007),
suggesting no role in binding CLEC-2. Intriguingly, threonine-
to-alanine conversions in the PLAG1 domains of the mouse,
rat, hamster, and dog abolish platelet aggregation (Kato et al.,
2003), indicating that species-specific O-glycosylation on the
first or last PLAG domain maintains a podoplanin-CLEC-2 inter-
action (Figure 4A). Our data suggest that the sialyl-Tn structure
(NeuAca2-6GalNAca1-O-Thr) in the PLAG3 domain is sufficient
for CLEC-2 binding. Consistent with this, a previous report
showed that human podoplanin with a sialyl-Tn structure
in the PLAG3 domain induces platelet aggregation (Amano
et al., 2008). The anti-podoplanin antibody NZ-1 reacts with21, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1715
AC
B
Figure 4. Amino Acid Sequence Alignment of Podoplanin, C-Type Lectin-like Snake Venom Proteins, and CLEC-2
(A) Sequence alignment of the podoplanin PLAG domains of human, mouse, rat, hamster and dog. The figure is modified from our previous report (Kaneko et al.,
2006).
(B) Sequence alignment of N-terminal parts of rhodocytin and related snake venom proteins. Three acidic residues that interact with CLEC-2 are indicated with
arrows above the sequence. The figure is modified from the report by Shin and Morita (1998).
(C) Amino acid sequence alignment of CLEC-2 lectin domains from human (UniProt ID code Q9P126), mouse (UniProt ID code Q9JL99), rat (GenBank ID code
ADK94892), hamster (GenBank ID code ERE66437), dog (GenBank ID code XP_543823), human DC-SIGN (GenBank ID code AAK20997), and human P-selectin
(GenBank ID code NP002996) were aligned by ClustalW. The secondary structure of human CLEC-2 is indicated. Amino acid residues that interact with po-
doplanin are highlighted in black. EPN and WND motifs that are critical for calcium binding in DC-SIGN and P-selectin are indicated by asterisks.
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Versatile Ligand Recognition Mechanism of CLEC-2the nonglycosylated podoplanin peptide, and the point muta-
tions of Met43 (PLAG2) and Asp49 (PLAG3) abolish binding to
NZ-1 (Figure 1A) (Fujii et al., 2014). It is likely that NZ-1 covers
PLAG2 and PLAG3, especially at the two acidic residues
(Glu47 and Asp48), and blocks access of CLEC-2. This supports
the idea that a two-locus interaction is essential for CLEC-2-
podoplanin binding. A sequence comparison of CLEC-2 among
different mammalian species highlights the conservation of the
four Arg residues Arg107, Arg118, Arg152, and Arg157 (human
protein numbering) responsible for binding podoplanin (Fig-
ure 4B). Three are especially conserved, although Arg118 is
replaced with lysine in the dog (Figure 4C). Our mutagenesis
study clearly shows that these electrostatic interactions between
podoplanin and CLEC-2 are essential for binding.
The simultaneous recognition of peptide and glycan moieties
of podoplanin by CLEC-2 must enhance affinity and form the
basis for the unique recognition of podoplanin among many
O-glycosylated proteins. The dissociation constant of CLEC-2
for podoplanin is 24 mM (Christou et al., 2008), which is suffi-
ciently strong and in line with other ligand-transmembrane re-
ceptor interactions. The binding motif of podoplanin, EDXXXT/S,1716 Structure 22, 1711–1721, December 2, 2014 ª2014 Elsevier Ltdwhere X is any amino acid and O-glycan is attached on T/S,
seems to be found ubiquitously in cellular proteins. However,
only 39 entries containing both the EDXXXT/S sequence and
O-glycan predicted at the T or S site are found in the UniProt
database (Table S3). Furthermore, several proteins are either
core proteins of proteoglycans, such as glypican-2 and synde-
can-1, or O-GlcNAclylated proteins, such as peroxisome pro-
liferator-activated receptor-g (PPARg). Because the sialylation
is essential for interaction, the endogenous binding partner
seems almost limited to being podoplanin. Although we cannot
exclude the possibility that a sialylation-independent ‘‘rhodocy-
tin-type’’ interaction exists endogenously, the short motif of
podoplanin must provide, at the very least, a highly selective
landmark for CLEC-2. Recent evidence suggests that, because
HIV-1-infected T cells do not express podoplanin, they possess
an as yet unidentified CLEC-2 ligand (Chaipan et al., 2010). It has
also been proposed that CLEC-2 expressed on neutrophils may
function as a pattern recognition receptor (Kerrigan et al., 2009).
Other possible endo- and exoligands of CLEC-2 may be identi-
fied using the recognition motif as a probe. Analogous with the
podoplanin-CLEC-2 interaction, a C-type lectin, P-selectin,All rights reserved
Figure 5. Crystal Structure of CLEC-2 in Complex with the Snake Venom Rhodocytin
(A) Overall structure of the CLEC-2 rhodocytin complex. The a and b subunits of rhodocytin and CLEC-2 molecules are shown in blue, orange, and green,
respectively.
(B) The interface between rhodocytin and CLEC-2. Rhodocytin and CLEC-2 are shown as wire and surface models, respectively. The four arginine residues of
CLEC-2 are labeled and highlighted in blue.
(C) The interaction between rhodocytin and CLEC-2. Complex 3 is shown as a representative structure. Hydrogen bond and electrostatic interaction networks are
shown as red dotted lines.
(D) Surface plasmon resonance assays. Rhodocytin was immobilized on a sensor chip, and wild-type CLEC-2 (black circle) and four mutants, R107A (green),
R118A (blue), R152A (red), and R157A (magenta), were analyzed at a series of concentrations.
Structure
Versatile Ligand Recognition Mechanism of CLEC-2binds O-glycan and sulfated tyrosine residues of P-selectin
glycoprotein-1 (PSGL-1) (Somers et al., 2000). Additionally, sia-
lylated O-glycan is essential in the recognition of the paired
immunoglobulin (Ig)-like type 2 receptor (PILR2) for endogenous
mouse CD99 (Kuroki et al., 2014; Wang et al., 2008) and exoge-
nous herpes simplex virus glycoprotein B (gB) (Wang et al.,
2009). From these observations, it is tempting to speculate that
O-glycans often assume a specific role as initial recognition
guides for target proteins, with subsequent involvement of adja-
cent amino acid residues.
The N-terminal sequence of the rhodocytin a subunit is very
similar to those of other C-type lectin-like venom proteins, but
the rhodocytin a subunit alone possesses the Glu-Asp doublet
(Figure 4B) (Shin and Morita, 1998). The doublet may be the
key for specific binding to CLEC-2. Crystallographic analyses
of other snake venom toxins (EMS16-Integrin a2-I domain, Bitis-
cetin-von Willebrand Factor A1 domain, and Factor-X binding
protein-Factor-X Gla domain) in complex with their target pro-
teins reveal that heterodimeric toxins bind to their target through
cavities formed by two subunits (Horii et al., 2004; Maita et al.,Structure 22, 1711–172003; Mizuno et al., 2001). In contrast, rhodocytin has a different
interaction mode with CLEC-2 (Figure S4). The area on CLEC-2
that contacts rhodocytin partially overlaps with that interacting
with podoplanin, and mutations to the same four arginines
dramatically reduce binding of both protein ligands. This sug-
gests that the toxin competes with podoplanin for binding to
CLEC-2. The identification of a ligand-binding site on CLEC-2
casts new light on its oligomerization and subsequent intracel-
lular signaling. Analysis of the stoichiometry of CLEC-2 on cells
suggests that it is normally a dimer but forms larger complexes
upon rhodocytin binding (Watson et al., 2009). The crystal pack-
ing of the rhodocytin complex shows that rhodocytin forms a
multimer by associating laterally (Figure S5) and that the inter-
action mode is different from that of the (ab)2 heterotetramer,
as reported in unliganded structures (Hooley et al., 2008;Watson
et al., 2008). In contrast, CLEC-2 molecules weakly dimerize in
the crystal at a site close to the a3-b3 loop region, which is on
a side opposite to the ligand binding site (Figure S6). This inter-
action may reflect a dimerization mode upon binding to a multi-
valent ligand. The human CLEC-2 gene (CLEC1B) is encoded in21, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1717
Figure 6. The Side Face of CLEC-2 Is
Utilized as a Platform for Ligand Binding
(A–D) CLEC-2 in complex with podoplanin (yellow)
or rhodocytin (blue) (A), P-selectin in complex
with PSGL-1 (PDB ID code 1G1S) (B), the NKG2D
dimer in complex with ULBP3 (PDB ID code
1KCG) (C), and the KACL dimer in complex with
NKp65 (PDB ID code 4IOP) (D) are shown.
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Versatile Ligand Recognition Mechanism of CLEC-2a natural killer gene complex (NKC) on chromosome 12, which
contains a group of C-type lectin receptor genes, including
NKG2 (A, C, D, E, and F), Ly49A-W, keratinocyte-associated
C-type lectin (KACL, also known asCLEC2A), andCD94. Several
C-type lectin receptors of NKC form homo- or heterodimers via
their C-type lectin domains (Radaev and Sun, 2003; Yokoyama
and Plougastel, 2003). Importantly, the ligand binding interface
of CLEC-2 we have elucidated partially overlaps the dimerization
interface of NKG2s, KACL, and Ly49s (a2 and b10, Figures 6C
and 6D). The putative dimerization interface of CLEC-2 contrasts
markedly with those of NKG2D and Ly49. The ligand interface
and crystal packing of CLEC-2 suggest its dimerization mode.
The structural basis for the specific interaction between
CLEC-2 and O-glycosylated podoplanin can now be under-
stood. Receptor specificity is critically dependent on a two-locus
interaction involving both the polypeptide and the carbohydrate
of podoplanin. It explains how a commonO-glycanmodification,
together with a particular adjoining peptide motif, can be
recognized as being unique. Such bifunctional recognition
could become a fundamental principle for specificity in recep-
tor-O-glycan ligand interactions. Furthermore, our elucidation
of a glycan-independent binding mode as seen in the CLEC-2-
rhodocytin interactionmay provide a basis for the rational design
of noncarbohydrate-based drugs that inhibit platelet-tumor
interaction (Kato et al., 2008) and CLEC-2-dependent HIV-1
spread in infected individuals (Chaipan et al., 2006).EXPERIMENTAL PROCEDURES
Expression and Purification of the CLEC-2 Lectin Domain
The extracellular lectin domain of CLEC-2 (C99Smutant) from residues 96–221
was cloned, expressed, and purified as reported previously, with slight
modifications (Watson and O’Callaghan, 2005). In brief, the CLEC-2 lectin
domain gene incorporated into the pCold-TEV vector was modified to include
a tobacco etch virus (TEV) protease cleavage sequence between the
hexahistidine tag and CLEC-2. The expression plasmid was introduced1718 Structure 22, 1711–1721, December 2, 2014 ª2014 Elsevier Ltd All rights reservedinto Escherichia coli strain Rosetta2 (DE3) (Nova-
gen, Merck Millipore). The hexahistidine-tagged
CLEC-2 protein was found in inclusion bodies.
The inclusion bodies were solubilized in 50 mM
2-(N-morpholino)ethanesulfonic acid (pH 6.5),
10 mM EDTA, 2 mM DTT, and 6 M guanidine hy-
drochloride at a protein concentration of 5 mg/ml.
Solubilized protein was diluted into 2 l of buffer
containing 150 mM Tris-HCl (pH 8.0), 1 M L-argi-
nine, 2 mM EDTA, 10 mM reduced glutathione,
and 0.5 mM oxidized glutathione. The mixture
was equilibrated at 4C for 16 hr with slow stirring
and then concentrated to a volume of 250 ml by
the QuixStand Benchtop system (GE Healthcare).
The concentrated protein solution was extensively
dialyzed against 2 l of buffer containing 20 mMTris-HCl (pH 8.0) and 100 mM NaCl at 4C. The dialyzed protein was then
purified by nickel-nitrilotriacetic acid chromatography. After removal of the
hexahistidine tag by TEV protease, the protein was further purified with size
exclusion column chromatography. Mutant CLEC-2 proteins (C99S/R107A,
C99S/R118A, C99S/R152A, and C99S/R157A) were expressed and purified
in the same manner. The purity of each protein was confirmed by SDS-
PAGE (Figure S7A, upper panel) and the proper folding of each mutant by
thermal shift assay (Figure S7B).
Purification of Rhodocytin from Calloselasma rhodostoma Venom
Lyophilized powder of pure venom from Calloselasma rhodostoma was pur-
chased from Latoxan. Rhodocytin was purified from the lyophilized powder
as reported previously (Shin and Morita, 1998). In brief, the lyophilized powder
was gently dissolved in a buffer containing 20 mM Tris-HCl (pH 8.0) and
100 mM NaCl. The dissolved solution was separated by centrifugation, and
the supernatant was subjected to gel filtration and anion exchange column
chromatography. The purity of rhodocytin was checked by SDS-PAGE
(Figure S7A, lower panel).
Crystallization of CLEC-2 Lectin Domains in Complex with
O-Glycosylated Podoplanin Peptide or Rhodocytin
Human podoplanin glycopeptide, including both the PLAG2 and PLAG3 do-
mains (Glu38–Gly54) and the disialyl core 1 O-glycan on Thr52, has been
synthesized and reported previously (Kato et al., 2008). An additional cysteine
residue (Cys55) was introduced at the C terminus of the peptide. For complex
formation, purified CLEC-2 protein was mixed with glycosylated peptide with
a 2-fold molar excess of glycopeptide and concentrated up to 57 mg/ml.
For the rhodocytin complex, purified rhodocytin was mixed with equal molar
amounts of CLEC-2 protein. The concentration was 45 mg/ml.
All crystals were obtained by the sitting drop vapor diffusion method using
0.8 ml drops containing a 50:50 (v/v) mix of protein and reservoir solution at
20C. The crystallization conditions were determined by screening using Index
(Hampton Research). Crystals of the CLEC-2-podoplanin peptide complex
were grown in a reservoir containing 0.1 M Tris-HCl (pH 8.5) and 25% (w/v)
polyethylene glycol (PEG) 3,350 (Index #45), and those of the CLEC-2-rhodo-
cytin complex were grown in a reservoir containing 0.1 M HEPES (pH 7.6),
0.2 M L-proline, and 10% (w/v) PEG 3,350.
Before X-ray diffraction experiments, crystals were soaked in reservoir
solution containing 20% (v/v) PEG400 and flash-cooled in liquid nitrogen.
X-ray diffraction data sets for the crystals were collected at the synchrotron
Figure 7. Two-Locus Interaction of CLEC-2
toward Podoplanin and Rhodocytin
(A) Superposition of two CLEC-2 molecules in two
complex structures. The CLEC-2 podoplanin
complex is shown in green and yellow, and the
CLEC-2 rhodocytin complex is shown in cyan and
blue. CLEC-2 molecules are shown as ribbon
models.
(B) Structural comparison of ligand binding sites.
The Glu-Asp doublet and the second site are
shown in the left and right panels, respectively.
The carboxyl groups at the second sites (Sia-4
in podoplanin, Asp6 and C-terminal Tyr136 in
rhodocytin) are indicated by red arrows in the
right panel. The four arginine residues in CLEC-2
are shown as stick and semitransparent sphere
models.
(C) Schematic of the two-locus interaction in the
CLEC-2-ligand complexes.
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Versatile Ligand Recognition Mechanism of CLEC-2radiation source at BL-5A and AR-NW12A in the Photon Factory. All data
sets were processed and scaled using the HKL2000 program suite (Otwi-
nowski and Minor, 1997). Phase determination was performed by the molec-
ular replacement method with ligand-free CLEC-2 (Protein Data Bank [PDB]
ID code 2C6U; Watson et al., 2007) and rhodocytin (PDB ID code 2VRP;
Watson et al., 2008) using MOLREP (Vagin and Teplyakov, 2010). Further
model building was performed manually using the program COOT (Emsley
and Cowtan, 2004). Refinement was conducted using REFMAC5 (Murshu-
dov et al., 1997). Of note, the data of the rhodocytin complex were diag-
nosed as twinned by CTRUNCATE of the CCP4 program suite (Collaborative
Computational Project, Number 4, 1994). Therefore, refinement was per-
formed using REFMAC5 with the twin refinement option. The stereochemical
quality of the final models was assessed by MolProbity (Lovell et al., 2003).
The MolProbity scores of podoplanin and rhodocytin complexes are 99th
and 96th percentiles, respectively. Data collection and refinement statistics
are summarized in Table 1. All figures were prepared with PyMOL (DeLano
Scientific).
Solution NMR Analysis of the CLEC-2-Podoplanin Interaction
1H-NMRdatawere obtained at a frequency of 500MHz using aDRX-500 spec-
trometer (BrukerBioSpin) equipped with a triple-resonance inverse cryogenic
probe. The CLEC-2 lectin domain (0.1 mM) was dissolved in 20 mM Tris-HCl
(pH 8.0), 100 mM NaCl, and 10% D2O/90% H2O, and the nonglycosylated
PLAG3 domain or glycosylated PLAG2-3 domain used in the crystallographic
study was added to the CLEC-2 solution. The probe temperature was set to
25C, and thewater signal was suppressed using awatergate pulse sequence.
Data processing was performed by XWIN-NMR (BrukerBiospin), and NMR
spectra were displayed using XWIN-PLOT (BrukerBiospin).
Flow Cytometric Analysis
The extracellular region of CLEC-2 (DN57) fused to the human Fc fragment was
expressed using CHO cells. Four CLEC-2-Fc mutants (R107A, R118A, R152A,
and R157A) were constructed in addition to wild-type CLEC-2. The expression
of eachmutant in culture supernatant was confirmed by western blotting using
anti-human IgG (Figure S7). Flow cytometric analysis was performed using the
CLEC-2-Fc chimera proteins and CHO cells expressing human podoplanin.
We initially tried to detect the binding between the monomeric CLEC-2 lectin
domain and podoplanin in the flow cytometric assay but were unsuccessful.
We therefore used Fc-fused CLEC-2 to enhance the apparent affinity toward
podoplanin on CHO cells.Structure 22, 1711–1721, December 2, 2014 ªSurface Plasmon Resonance Assay
A surface plasmon resonance assay was per-
formed with BIACORE 2000 (GE Healthcare).
Rhodocytin was directly captured on a sensor
chip (CM5, GE Healthcare) by amine coupling.A series of CLEC-2 lectin domain mutants were used as analytes at a flow
rate of 20 ml/min. After each run, bound CLEC-2 protein was completely
stripped off from the ligand by regeneration of the surface with 3 M magne-
sium chloride. We calculated the dissociation constants of monomeric
CLEC-2 lectin domain using a 1:1 steady-state binding model: Req = C 3
Rmax / (KD + C), where C is the analyte CLEC-2 concentrations, Rmax is
the maximum binding response, and KD is the equilibrium dissociation
constant.
Database Analysis
A comprehensive sequence motif search was performed against all
deposited entries (544,996 entries) of the UniProtKB/SWISS-PROT data-
base as of April 2014. The potential O-glycosylation site was assigned
based on the annotation (FT column) of each entry. During the course of
the analysis, we realized that annotated O-glycosylation sites in UniProt
seem to include glycosaminoglycan (GAG)-linked Ser in addition to
Ser/Thr-linked mucin-type O-glycans. Because no suitable method is avail-
able to select the mucin-type O-glycosylation sites, GAG-linked sites are
included in Table S3.
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